Pfizer: Carcinoma, Transitional Cell trials

The registry lists 14 Carcinoma, Transitional Cell studies with Pfizer as lead sponsor. 4 are open to participants now and 4 have results posted.

Phase 1 6Phase 2 2Phase 3 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Real-world Study to Learn About of the Characteristics and Outcomes of Advanced or Metastatic Bladder Cancer Patients With Different HistologiesNot yet recruitingNCT07897669
• Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerRecruitingNCT07421700Phase 1/2
• A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 1
• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2RecruitingNCT04879329Phase 2
• A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMACompletedNCT04822350Results posted
• Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsTerminatedNCT04628780Phase 1Results posted
• A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)CompletedNCT02603432Phase 3Results posted
• A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid TumorsCompletedNCT02573259Phase 1Results posted
• A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder CancerCompletedNCT07386847
• A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1
• Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active, not recruitingNCT05911295Phase 3
• HER2 and LA/mUC: A Multi-country Chart Review Cohort StudyCompletedNCT05902494
• A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder CancerTerminatedNCT05699135
• Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1